Cue Biopharma Inc (NAS:CUE)
$ 1.64 0.02 (1.23%) Market Cap: 79.78 Mil Enterprise Value: 51.26 Mil PE Ratio: 0 PB Ratio: 2.66 GF Score: 52/100

Q3 2022 Cue Biopharma Inc Earnings Call Transcript

Nov 14, 2022 / 09:30PM GMT
Release Date Price: $3.25 (+3.50%)
Operator

Greetings, and welcome to the Cue Biopharma Update Call. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to turn the conference over to Dan Passeri, Cue Biopharma's Chief Executive Officer. Thank you, sir. Please begin.

Daniel R. Passeri
Cue Biopharma, Inc. - CEO & Director

Thank you, and good afternoon, everyone. Before I begin, I'd like to remind everyone that you have the slides in front of you that you need to operate manually, and we will notify you what slide we are on.

Joining me on today's call is Dr. Anish Suri, our President and CSO; Dr. Ken Pienta, our Acting Chief Medical Officer; and Dr. Matteo Levisetti, our Senior Vice President of Clinical Development; as well as Kerri Millar, our Chief Financial Officer. This conference is being recorded and will be available on our website for the next 30 days.

As a reminder, and as shown here on Slide #2, this presentation and overview may contain some forward-looking statements, and any forward-looking statements made during this

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot